Relaxofen

Raloxifene (Evista) for Osteoporosis and Breast Cancer Prevention

Raloxifene is a medication specifically designed to help postmenopausal women prevent and treat osteoporosis, a condition characterized by thinning and weakening of the bones. It works by mimicking the effects of estrogen in bones, which helps to strengthen them and reduce the risk of fractures. However, unlike estrogen, raloxifene does not stimulate the breast or uterus, making it a safer option for women with osteoporosis.

In addition to its bone-strengthening properties, raloxifene also lowers the risk of developing invasive breast cancer. It achieves this by blocking estrogen activity in breast tissue, which prevents the growth of breast cancer cells.

Common side effects of raloxifene include hot flashes, joint pain, and increased white vaginal discharge. It is available in 60 mg oral tablets and should only be taken under the guidance of a healthcare provider.

Raloxifene is particularly beneficial for postmenopausal women who are at high risk of osteoporosis or breast cancer. By using this medication, women can significantly reduce their risk of bone fractures and breast cancer, improving their overall health and well-being. Always consult with your healthcare provider before starting any new medication.